2gqg
From Proteopedia
|
X-ray Crystal Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain
Contents |
Overview
Chronic myeloid leukemia (CML) is caused by the constitutively activated, tyrosine kinase breakpoint cluster (BCR)-ABL. Current frontline therapy, for CML is imatinib, an inhibitor of BCR-ABL. Although imatinib has a high, rate of clinical success in early phase CML, treatment resistance is, problematic, particularly in later stages of the disease, and is, frequently mediated by mutations in BCR-ABL. Dasatinib (BMS-354825) is a, multitargeted tyrosine kinase inhibitor that targets oncogenic pathways, and is a more potent inhibitor than imatinib against wild-type BCR-ABL. It, has also shown preclinical activity against all but one of the, imatinib-resistant BCR-ABL mutants tested to date. Analysis of the crystal, structure of dasatinib-bound ABL kinase suggests that the increased, binding affinity of dasatinib over imatinib is at least partially due to, its ability to recognize multiple states of BCR-ABL. The structure also, provides an explanation for the activity of dasatinib against, imatinib-resistant BCR-ABL mutants.
Disease
Known diseases associated with this structure: Leukemia, Philadelphia chromosome-positive, resistant to imatinib OMIM:[189980]
About this Structure
2GQG is a Single protein structure of sequence from Homo sapiens with 1N1 and GOL as ligands. Active as Non-specific protein-tyrosine kinase, with EC number 2.7.10.2 Full crystallographic information is available from OCA.
Reference
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants., Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, Xie D, Zhang Y, Klei HE, Cancer Res. 2006 Jun 1;66(11):5790-7. PMID:16740718
Page seeded by OCA on Mon Nov 12 22:21:06 2007
